# Bayer Acquires Perfuse in $2.45 Billion Deal

Page: https://stenobird.com/podcast/eyewire-news-the-podcast-7055536/bayer-acquires-perfuse-in-2-45-billion-deal
Text version: https://stenobird.com/podcast/eyewire-news-the-podcast-7055536/bayer-acquires-perfuse-in-2-45-billion-deal.md
Podcast: [Eyewire News: The Podcast](https://stenobird.com/podcast/eyewire-news-the-podcast-7055536)
Published: 2026-05-06T18:40:00+00:00
Episode link: https://traffic.megaphone.fm/BMCL7214816195.mp3
Audio file: https://traffic.megaphone.fm/BMCL7214816195.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/bayer-acquires-perfuse-in-2-45-billion-deal
Duration seconds: 410

## Resource

Bayer expands ophthalmology pipeline with acquisiton of Perfuse Therapeutics; Viridian announces new phase 3 data for its investigational subcutaneous injection for chronic thyroid eye disease; and Steven Dell, MD discusses the impact of declining reimbursement could on ophthalmic practices. Learn more about your ad choices. Visit megaphone.fm/adchoices

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/bayer-acquires-perfuse-in-2-45-billion-deal/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/eyewire-news-the-podcast-7055536/bayer-acquires-perfuse-in-2-45-billion-deal.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.